Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

Baselga, José; Vf, Semiglazov; van Dam, Peter; Manikhas, Alexey; Bellet, Meritxell; Mayordomo, José; Campone, Mario; Kubista, E.; Greil, Richard; Bianchi, Giulia; Steinseifer, Jutta; Molloy, Betty; Tokaji, Erika; Gardner, Humphrey; Phillips, Penny; Stumm, Michael; A. Lane, Heidi; Michael Dixon, J.; Jonat, W.; S. Rugo, Hope

doi:10.1200/jco.2008.18.8391

Public

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

Published in Journal of Clinical Oncology • Apr 21, 2009

Authors:

José Baselga

Semiglazov Vf

Peter van Dam

Abstract

PURPOSE: Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and blockade of both pathways enhances antitumor activity in preclinical models. This study explored wh...

Subject

Letrozole

Everolimus

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!